Naloxone suppresses intake of highly preferred saccharin solutions in food deprived and sated rats

Centrally administered opioid peptides stimulate saccharin intake in nondeprived rats

Endogenous opioid peptides are thought to play a role in mediating the pleasurable or rewarding aspects of the ingestion of certain foods and liquids. We therefore measured the effects of central administration of selective opioid agonists and naloxone on the intake of two concentrations of saccharin solution. All tests were performed on nondeprived rats, such that the taste of the solutions provided the primary incentive to consume. Intracerebroventricular (ICV) administration of the selective mu agonist [D-Ala2,MePhe4,Gly-ol5]enkephalin (DAGO) and the selective delta agonist Tyr-D-Thr-Gly-Phe-Leu-Thr (DTLET) (3 nmol) increased intake of a 0.15% saccharin solution by approximately 10 ml over 3 hr. Water was available simultaneously, but intake was minimal. The selective kappa agonist U-50,488H did not increase intake of the saccharin solution. Naloxone (30 and 100 micrograms, ICV) caused a 44% reduction in saccharin solution intake in the first hour; two- and three-hour cumulative intakes were not different from control. DAGO and DTLET were also tested when rats were given a weaker saccharin solution (0.006%) along with water. Both agonists caused small increases in saccharin and water intake, but the increases above baseline were much smaller than those observed with the more palatable 0.15% saccharin solution. These results are consistent with reports by others which suggest that endogenous opioids influence taste preferences or palatability. Further, they indicate a role for central mu and delta opioid receptors in the mediation of this influence.

Central vs. peripheral mediation of opioid effects on alcohol consumption in free-feeding rats

Although there is considerable evidence that pretreatment with low doses of opioid agonists can enhance, and opioid antagonists can reduce alcohol consumption in rats, little is known about the locus or mechanism of these effects. As a first approximation as to where the effect may occur, we compared the effects of an opioid agonist morphine (1, 3 and 10 mg/kg) and antagonist naltrexone (1, 3 and 10 mg/kg) that are known to act within the brain as well as the periphery, to those of an agonist-like drug loperamide (0.3, 1 and 3 mg/kg) and an antagonist methylnaltrexone (3, 10 and 30 mg/kg) that are known to act peripherally only. Free-feeding rats were initially trained to drink alcohol using a limited access paradigm, and when animals were drinking asymptotic amounts of 12% (w/v) alcohol, increasing doses of one of the four drugs or saline were administered IP to separate groups of rats 30 min prior to the hour-long daily drinking session. The results confirmed that the effects of the opioids on alcohol consumption are indeed mediated within the central nervous system in that morphine enhanced alcohol consumption but loperamide did not, naltrexone reduced alcohol consumption but methylnaltrexone did not, and naltrexone was able to block the morphine effect but methylnaltrexone failed to do so. An unexpected finding was that methylnaltrexone alone also increased alcohol consumption. Possible means by which this could occur, also supporting the idea of a central locus for the effect, as well as possible mechanisms by which opioids could influence alcohol consumption generally, are discussed.

Effects of naltrexone on food preference and concurrent behavioral responses in food-deprived rats

Naltrexone (0.05-5.0 mg/kg, SC) was administered to food-deprived rats prior to a 15-min food-preference test. Total food intake and feeding duration was reduced following administration of the opiate antagonist. However, while naltrexone reduced the consumption of the initially-preferred chocolate-coated cookies, the ingestion of the nonpreferred standard laboratory chow pellets was significantly enhanced. These data cannot be explained in terms of a general anorexic effect and nonspecific suppression of feeding responses. Instead, they indicate that naltrexone reduced preference for the highly palatable cookies, so that a feeding response to the chow pellets emerged. Under the conditions of test-familiarity, naltrexone did not reduce grooming, locomotion or rearing duration. An increase in locomotion may have been secondary to the reduction in feeding. The results agree with previous data from animal and human studies in suggesting that endogenous opioid peptide activity is involved in the palatability of preferred foods.

Beta-endorphin administration interferes with the acquisition and initial maintenance of ethanol preference in the rat

Attention has been focused on the possibility of an interaction between the endorphinergic system and ethanol intake. In the present study, the effects of subcutaneous (SC) administration of beta-endorphin (beta-E) (0.25, 1 and 5 micrograms/kg) and/or naloxone (NX) (1 or 2.5 mg/kg) on ethanol preference (EP) have been investigated in rats. Under our procedural conditions, rats developed ethanol preference (EP) by a forced ethanol drinking session (conditioning session). Preconditioning administration of beta-E (1 microgram/kg) reduced later EP. When beta-E was administered postconditioning, the opioid affects ethanol preference depending on the dose: both 0.25 micrograms/kg and 5 microgram/kg reduced EP, but the dose of 1 microgram/kg did not alter it. Administration of beta-E (1 and 5 micrograms/kg) before the first testing session attenuated EP. NX antagonized the effects of beta-E on EP in the three experimental procedures used, indicating that mu-opioid receptors might be involved in the beta-E-induced reductions on EP. Our results provide further evidences for a beta-endorphinergic system involvement on the mechanism leading to consumption of ethanol.

Chronic sweet intake lowers pain thresholds without changing brain mu- or delta-opiate receptors

Sprague-Dawley rats drank sweetened (3% dextrose + 0.144% saccharin, w/v) or unflavored water for 18 days and subsequent pain reactivity was assessed using a hot plate. Compared to the rats that consumed unflavored water, the rats that consumed sweet water responded more quickly on the hot plate indicating that their threshold for pain was lowered. Another group of rats given identical exposure to the fluids had their brains prepared for measuring opiate receptor binding using the delta-receptor ligand [3H]D-Ala-D-Leu-enkephalin ([3H]DADLE) and the mu-receptor selective ligand [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol ([ 3H]DAGO). Binding of these opiates to mu- and delta-receptors in the cerebral cortex, striatum, hippocampus, hypothalamus, brain stem, and remaining brain regions was the same for the rats that drank sweet fluids and those that drank unflavored water. These findings suggest that drinking sweet fluids lowers pain thresholds but does not alter mu- and delta-receptors.

Interaction between opioid agonists or naloxone and 5-HTP on feeding behavior in food-deprived rats

Morphine and the enkephalin analogs DAME, DADLE and FK-33824, as well as the opioid antagonist naloxone, decrease feeding in food-deprived rats after intraventricular or subcutaneous administration, FK-33824 being by far the most potent drug tested. The administration of subeffective doses of either morphine or naloxone given by the subcutaneous route induces anorexia when given in combination with a subeffective dose of 5-HTP whereas the treatment with subeffective intraventricular doses of any of the opioids or naloxone fails to potentiate 5-HTP. Similarly, the anorexia induced by FK-33824 is blocked by either morphine or naloxone given subcutaneously but not by intraventricular administration of the same two drugs. The results appear to suggest that central or peripheral opioid receptors differentially affect feeding behavior in the rat and, on the other hand, that the interaction of opiates with the serotonergic system appears to occur preferentially in the periphery.

Reduced saccharin preference in CXBK (opioid receptor-deficient) mice

The preference for sweet solutions in opioid receptor-deficient (CXBK) and control (C57BL/6By) mice was compared. CXBK and C57BL/6By (C57) mice were presented for 2 h/day with 2 tubes, one always containing water and the other containing either water or various concentrations of saccharin solution. Fifteen minutes before the drinking session, half of the mice in each strain were injected with naltrexone (0.2 mg/kg) and the other half with saline. Compared to C57 mice, CXBK mice had significantly lower saccharin preference. Naltrexone reduced the saccharin preference in both strains, almost completely abolishing preference in CXBK mice. The results support the hypothesis that brain opioid receptors are involved in mediating sweet palatability and suggest that genetic differences in opioid receptor density contribute to differences in the palatability of sweet solutions.

Responsivity to pain in rats changed by the ingestion of flavored water

Sprague-Dawley male rats drank flavored water and subsequent pain responsivity was assessed using a hot plate first after isotonic saline and later after either 2.75 (Experiment 1) or 2.5 (Experiment 2) mg/kg of morphine hydrochloride was injected. A 48-h exposure to any one of several different flavors resulted in a reduction of the analgesic effects of morphine as shown by an attenuation of the increased latency to paw lick caused by the morphine. This effect was independent of the amount consumed. A 26-h exposure to a flavor decreased pain reactivity before and after morphine as shown by an overall increase in latency to paw lick. This effect was not influenced by whether the normally preferred flavor was made aversive by a previous pairing with lithium chloride-induced illness. These findings are consistent with the idea that many flavors, independently of palatability and amount consumed, increase the release and utilization of endogenous opioids.

Attenuation of sham feeding by naloxone is stereospecific: evidence for opioid mediation of orosensory reward

The time course of the suppressive action of naloxone on sham feeding was examined in gastric fistulated rats. One hour sham intake of 30% sucrose solution was halved by 1.25 mg/kg IP (-)-naloxone. A maximal 75% reduction was obtained with 2.5 mg/kg. Naloxone's effect appeared to mimic the attenuation of intake rate produced by sucrose dilution. The stereoisomer (+)-naloxone (1.25, 2.5 and 10 mg/kg IP) was ineffective. These data confirm the involvement of opioid receptors in naloxone anorexia and are consistent with opioid involvement in the rewarding aspects of ingestion.

Anorexia in the elderly

Weight loss and anorexia occur commonly in the elderly. While in many cases the anorexia can be attributed to associated disease processes, it does appear that a true anorexia of aging exists. Animal studies have suggested that older rodents have an excessive satiety effect of cholecystokinin and a decreased opioid feeding drive. Other older persons develop anorexia in association with depression. In these subjects, excess corticotropin-releasing factor may be the neurotransmitter involved in the pathogenesis of the anorexia. In Alzheimer's disease, decreases in norepinephrine and neuropeptide Y may be involved in the anorexia seen in the these patients.

Naloxone decreases ethanol consumption within a free choice paradigm in rats

The effect of subcutaneous naloxone administration on the consumption of a weak ethanol solution in rats on the three consecutive days (testing days) was investigated using a behavioral paradigm which includes a first forced ethanol exposure (conditioning day) followed by a two-bottle ethanol/water choice procedure. Besides reducing fluid intake, naloxone treatment prior to forced ethanol exposure interferes with the acquisition of ethanol preference. Post-conditioning naloxone administration fails to affect ethanol preference. Administration of naloxone prior to the first testing session induces a reduction on total fluid intake, at the day of treatment; a decrease on ethanol preference throughout the three consecutive testing days is also observed with the higher dose of the antagonist (5 mg/kg). An involvement of endogenous opioids in ethanol consumption is suggested through the modulation of alcohol reinforcement or the affective quality of the gustatory cue.

Naloxone attenuation of sham feeding is modified by manipulation of sucrose concentration

The time course of sucrose (5, 10 and 20%; w/v) sham feeding was monitored in one hour tests. Intake levels increased as a function of concentration. Naloxone (1.25 mg/kg, IP) attenuated the sham feeding of 10% sucrose solution in gastric fistulated rats, without affecting initial intake rates. Furthermore, after naloxone the intake pattern of 10% sucrose was identical to that for 5% sucrose in untreated rats. In a second test, substitution of 10% sucrose by a 20% solution after 15 min of sham feeding reversed the effect of naloxone, restoring intake to 10% baseline levels. Thus naloxone's effect appeared to be behaviourally equivalent to that of sucrose dilution and was counteracted by increasing sucrose concentration. Naloxone was apparently more effective against the lower sucrose concentration, suppressing intake at an earlier stage of testing. The data confirm the importance of oropharyngeal stimulation to the suppressive action of naloxone and support opioid mediation of orosensory reward.

Bidirectional changes in the consumption of food produced by beta-carbolines

beta-Carboline derivatives provide examples of benzodiazepine receptor ligands which span the range: full agonist-partial agonist-antagonist-partial inverse agonist-full inverse agonist. Taken together, the effects of these compounds illustrate two important principles: firstly, the bidirectionality of effects which can be achieved using benzodiazepine receptor ligands; secondly, the selectivity of effects which are produced by partial agonists. Applied to the study of feeding processes, these principles imply that both hyperphagic and anorectic effects can be generated by actions of selected ligands at benzodiazepine receptors. Furthermore, they suggest that a hyperphagic effect may occur in the absence of side-effects (e.g., sedation, muscle-relaxation), which are characteristic of classical benzodiazepines. Experimental data in support of these predictions are presented. A microstructural approach to feeding behavior indicated that a benzodiazepine receptor agonist and an inverse agonist extend and abbreviate, respectively, the duration of individual bouts of eating. Preference for a saccharin solution was attenuated by the beta-carboline inverse agonist, FG 7142, but rejection of a quinine solution was not increased. Adrenalectomy had no effect on the anorectic effect of inverse agonists.

Adrenalectomy and the anorectic effects of benzodiazepine inverse agonists and opiate antagonists in rats fed a palatable diet

The benzodiazepine (BZ) receptor inverse agonists, FG 7142 (1.25-10.0 mg/kg, IP) and CGS 8216 (2.5-20.0 mg/kg, IP), significantly attenuated the consumption of a palatable sweetened diet by non-deprived male rats in a 30 min test. Adrenalectomy failed to affect the reduction in food intake produced by these two drugs. Similarly, the anorectic effects of the opiate antagonists, naltrexone (0.3-3.0 mg/kg, SC) and diprenorphine (0.3-3.0 mg/kg, SC) in the same feeding paradigm were unaffected by adrenalectomy. So far as palatability-induced feeding in concerned, anorectic effects of BZ inverse agonists and opiate-antagonists appear to be adrenal-independent in the rat. The benzodiazepines, clonazepam (0.3 mg/kg, IP) and diazepam (1.0 mg/kg, IP), stimulated food consumption in both adrenalectomized and sham-operated animals.

Effects of food deprivation and high fat diet on opioid receptor binding in rat brain

The effect of food deprivation for 72 h or a high fat diet on [3H]naloxone binding in the discrete brain regions of male lean Zucker rats was studied. In the midbrain, both treatments increased Bmax for the high-affinity site with no change in Kd. In the cortex, the high fat diet increased Bmax for the high-affinity site. These results suggest that dietary manipulations could produce significant changes in the endogenous opioid system.

CGS 8216, a novel anorectic agent, selectively reduces saccharin solution consumption in the rat

The pyrazoloquinoline CGS 8216, a high-affinity ligand for benzodiazepine recognition sites, significantly reduced the consumption of a preferred 0.05% sodium saccharin solution in a 30 min two-bottle test. A highly significant effect was detected at 5.0 mg/kg, IP and at higher doses. The consumption of water and 0.6% saline, in two-bottle tests, or of quinine solution and water, in a forced-choice test, was not reliably affected by CGS 8216. The results point to a sensitive and selective intrinsic effect of CGS 8216 on ingestional responses in the rat.

Opiate blockade inhibits saccharin intake and blocks normal preference acquisition

Recent evidence indicates a close connection between oral sensory function and opioid effects on feeding. Not only is gustatory motivation influenced by opiate drugs but apparently gustatory stimuli can also activate central opiate receptor systems. In 3 experiments we studied the effect of opiate receptor blockade on drinking motivated by the sweet taste of saccharin. Experiment 1 established a dose-response function for inhibition of intake by naloxone (NAL) in short (60 min) 2-bottle tests. This experiment demonstrated the extreme sensitivity of nondeprived, nonstressed animals to NAL and estimated the MED50 at less than 0.1 mg/kg (SC), well below the threshold for effects due to illness or general motor disturbance. Experiment 2 further demonstrated that NAL's effectiveness depends on saccharin concentration. In particular, the lowest NAL dose studied was effective near the threshold for saccharin preference but not at higher concentrations. These data suggest that endogenous opioid systems may be activated by taste stimuli in a graded fashion. Finally, experiment 3 showed that the typical acquisition of preference for a moderate saccharin concentration can be effectively blocked by daily pre-test NAL injection. Together these experiments further demonstrate the close functional relationship between opioid systems and gustatory sensory systems.

Endorphins and food intake: kappa opioid receptor agonists and hyperphagia

Evidence from studies which utilise either opiate receptor agonists and antagonists strongly indicate a role for endorphinergic mechanisms in the control of feeding responses. Two means by which these compounds may exert an effect on feeding can be singled-out. Firstly, emerging evidence suggests that the process of achieving satiety (terminating a meal, or choice of a commodity) may be accelerated following treatments with opiate receptor antagonists. Secondly, the preference for highly palatable solutions (sweet solutions have received most attention) in two-bottle tests is blocked after injection of opiate receptor antagonists. This finding has been interpreted in terms of the abolition of the reward or incentive quality associated with the particularly attractive flavour. These two mechanisms of action may represent two aspects of a single, fundamental process. Following an introduction to rat urination model of in vivo kappa agonist activity, the consistent effect of several kappa agonists (including the highly selective U-50,488H) to stimulate food consumption is described. Recognising that members of the dynorphin group of endogenous opioid peptides are kappa receptor ligands, some with a high degree of selectivity, and the evidence the dynorphins and neo-endorphins produce hyperphagia in rats is particularly interesting. Such lines of evidence lead to the hypothesis that peptides of the dynorphin group may act endogenously to promote the expression of normal feeding behaviour.

Autoradiographic localization of kappa opiate receptors in CNS taste and feeding areas

Recent evidence suggests that kappa opiate receptors may play a key role in the regulation of appetite. Such evidence implies that kappa receptors might be localized within specific brain areas known to regulate ingestive behaviors. On the basis of this implication we employed an in vitro film autoradiographic technique using 3H-ethylketocyclazozine as ligand to identify putative kappa receptors within CNS "taste" nuclei and surrounding areas. Coronal cryostat sections of rat brain were incubated with ligand in the presence of D-Ala2, D-Leu5-enkephalin (DADLE) and morphine, apposed to LKB Ultrofilm for 60 days, processed and kappa receptor densities evaluated with the aid of a hand held photometer and video image analyzer. Highest kappa receptor densities were found within various gustatory and feeding sites including the rostral pole of the nucleus of the solitary tract, parabrachial nuclei, ventral posterior and medial portions of the thalamus, medial hypothalamus, medial nuclei of the amygdala and bed nucleus of the stria terminalis. Various other midline and medial limbic areas also showed significant kappa densities.

Inhibition of mating by naloxone or morphine in recently castrated, but not intact male rats

Administration of naloxone (SC 5 mg/kg) significantly reduced ejaculation and mounting in male rats in the weeks following castration. A similar effect was obtained by injecting morphine (SC 1 or 5 mg/kg). In contrast, the same dosages of naloxone or morphine did not affect the sexual performance of gonadally intact males. Opioid peptides may contribute to the temporary persistence of sexual behavior in testosterone-deficient male mammals, in which incentive qualities of the female partner are an important determinant of sexual arousal.

Isolation and striatal (3H) serotonin uptake: role in the voluntary intake of ethanol by rats

Ethanol preferring rats were selected and showed a constant voluntary intake of a 12 percent ethanol solution during 14 days (about 5 g/kg body weight daily). Analysis of 3H serotonin uptake by striatal synaptosomes showed that steady state 3H serotonin synaptosomal levels were lower in alcohol preferring rats. Grouping these rats (5 per cage) reduced both voluntary intake of ethanol and synaptosomal 3H serotonin uptake. Furthermore, blocking the serotonin uptake by clomipramine 5 mg X kg-1 or 10 mg X kg-1 also reduces voluntary intake of ethanol. These data are in agreement with the hypothesis of a modulation of the voluntary intake of ethanol both by chemical and housing stimulation of striatal receptors for serotonin.